Maintenance therapy for acute myeloid leukemia in remission
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a maintenance therapy called ABC (likely a combination of drugs) to see if it can keep adults with acute myeloid leukemia (AML) in remission longer after their first successful treatment. The goal is to prevent the leukemia from coming back and improve overall survival.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old and have been diagnosed with acute myeloid leukemia (AML) for the first time
- You have completed initial intensive chemotherapy and at least two rounds of consolidation therapy, and are now in your first complete remission (no visible leukemia) within the last 4 months
- You are in adequate general health, able to perform most daily activities (performance status 3 or better)
- If you are of childbearing potential, you must have negative pregnancy tests before starting and agree to use two reliable birth control methods during treatment and for 28 days after
- You have not had a stem cell transplant, and you do not have certain types of AML (like acute promyelocytic leukemia) or active leukemia in the brain or spinal fluid
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies azacytidine (AZA) plus venetoclax as maintenance treatment to help keep acute myeloid leukemia (AML) in first remission. It may help delay or prevent AML from returning in younger adults who cannot get a stem cell transplant right away.
This Phase 1 trial tests whether continuing decitabine alone or with other targeted drugs can help prevent AML from coming back after you reach remission. It’s designed to study safety and how well these maintenance options work for people who are not immediately able to get a stem cell transplant.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This trial is for people with acute myeloid leukemia (AML) who are in remission but still have tiny traces of leukemia cells that can be found with sensitive tests (called MRD-positive). The study is testing a new treatment approach to try to get rid of those remaining cells and prevent the cancer from coming back.
This trial tests a new type of maintenance therapy for acute myeloid leukemia (AML) patients who have already responded well to chemotherapy. The treatment uses your own immune cells to help prevent the cancer from coming back.
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
Hear when a new Acute Myeloid Leukemia (AML) in Remission trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.